Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease

Paolo Zanoni(Translational Therapeutics (United States)), Sumeet A. Khetarpal(Translational Therapeutics (United States)), Daniel B. Larach(Translational Therapeutics (United States)), William Hancock‐Cerutti(Inserm), John S. Millar(Translational Therapeutics (United States)), Marina Cuchel(Translational Therapeutics (United States)), Stephanie DerOhannessian(Translational Therapeutics (United States)), Anatol Kontush(Inserm), Praveen Surendran(University of Cambridge), Danish Saleheen(University of Cambridge), Stella Trompet(Leiden University Medical Center), J. Wouter Jukema(Leiden University Medical Center), Anton de Craen(Leiden University Medical Center), Panos Deloukas(Wellcome Sanger Institute), Naveed Sattar(British Heart Foundation), Ian Ford(University of Glasgow), Chris J. Packard(Western Infirmary), Abdullah Al Shafi Majumder(National Institute of Cardiovascular Diseases), Dewan S Alam(International Centre for Diarrhoeal Disease Research), Emanuele Di Angelantonio(University of Cambridge), Gonçalo R. Abecasis(University of Michigan), Rajiv Chowdhury(University of Cambridge), Jeanette Erdmann(Institute for Integrative and Experimental Genomics), Børge G. Nordestgaard(Herlev Hospital), Sune F. Nielsen(Herlev Hospital), Anne Tybjærg‐Hansen(University of Copenhagen), Ruth Frikke‐Schmidt(University of Copenhagen), Kari Kuulasmaa(Finnish Institute for Health and Welfare), Dajiang J. Liu(Pennsylvania State University), Markus Perola(University of Helsinki), Stefan Blankenberg(Universität Hamburg), Veikko Salomaa(Finnish Institute for Health and Welfare), Satu Männistö(Finnish Institute for Health and Welfare), Philippe Amouyel(Institut Pasteur de Lille), Dominique Arveiler(Université de Strasbourg), Jean Ferrières(Université Fédérale de Toulouse Midi-Pyrénées), Martina Müller‐Nurasyid(Helmholtz Zentrum München), Maurizio Ferrario(University of Insubria), Frank Kee(Queens University), Cristen J. Willer(University of Michigan), Nilesh J. Samani(University of Leicester), Heribert Schunkert(Deutsches Herzzentrum München), Adam S. Butterworth(University of Cambridge), Joanna M. M. Howson(University of Cambridge), Gina M. Peloso(Broad Institute), Nathan O. Stitziel(Washington University in St. Louis), John Danesh(University of Cambridge), Sekar Kathiresan(Broad Institute), Daniel J. Rader(Translational Therapeutics (United States)), Sarah Watson, Ellen M. Schmidt(University of Copenhagen), Sebanti Sengupta, Stefan Gustafsson(Universität Hamburg), Stavroula Kanoni, Andrea Ganna, Jin Chen, Martin L. Buchkovich, Samia Mora, J. Beckmann, Jennifer L. Bragg‐Gresham, Hsing‐Yi Chang, Ayşe Demirkan, Heleen M. den Hertog, Ron Do(Université de Strasbourg), Louise A. Donnelly, Georg Ehret, Tõnu Esko, Mary F. Feitosa, Teresa Ferreira, Krista Fischer, Pierre Fontanillas, Ross M. Fraser, Daniel F. Freitag, Deepti Gurdasani, Kauko Heikkilä, Elina Hyppönen, Aaron Isaacs, Anne Jackson, Åsa Johansson, Toby Johnson, Marika Kaakinen, Johannes Kettunen, Marcus E. Kleber, Xiaohui Li(Institut Pasteur de Lille), Jian’an Luan, Leo‐Pekka Lyytikäinen, Patrik K. E. Magnusson, Massimo Mangino, Evelin Mihailov, May E. Montasser, Ilja M. Nolte, Jeffrey R. O’Connell, Cameron D. Palmer, Ann-Kristin Petersen, Serena Sanna, Richa Saxena, Susan K. Service, Sonia Shah, Dmitry Shungin, Carlo Sidore, Ci Song, Rona J. Strawbridge, Ida Surakka, Toshiko Tanaka, Tanya M. Teslovich, Guðmar Þorleifsson, Evita G. van den Herik, Benjamin F. Voight, Kelly A. Volcik, Lindsay L. Waite, Andrew Wong, Ying Wu, Weihua Zhang, Devin Absher, Gershim Asiki, Inês Barroso, Latonya Been, Jennifer L. Bolton, Lori L. Bonnycastle, Paolo Brambilla(Translational Therapeutics (United States)), Mary Susan Burnett, Giancarlo Cesana, Maria Dimitriou, Alex S. F. Doney, Angela Döring(University of Cambridge), Paul Elliott, Stephen E. Epstein, Guðmundur I. Eyjólfsson, Bruna Gigante, Mark O. Goodarzi, Harald Grallert, Martha L. Gravito, Christopher J. Groves, Göran Hallmans, Anna‐Liisa Hartikainen, Caroline Hayward, Dena Hernandez, Andrew A. Hicks, Hilma Hólm, Yi‐Jen Hung, Thomas Illig, Michelle R. Jones, Pontiano Kaleebu, John J.P. Kastelein, Kay‐Tee Khaw, Eric H. Kim, Norman Klopp, Pirjo Komulainen, Meena Kumari, Claudia Langenberg, Terho Lehtimäki, Shih-Yi Lin, Jaana Lindström, Ruth J. F. Loos, François Mach, Wendy L. McArdle, Christa Meisinger, Braxton D. Mitchell, Gabrielle Müller(Helmholtz Zentrum München), Ramaiah Nagaraja, Narisu Narisu, Tuomo Nieminen, Rebecca N. Nsubuga, Ísleifur Ólafsson, Ken K. Ong, Aarno Palotie, Theodore Papamarkou, Cristina Pomilla, Anneli Pouta, Muredach P. Reilly, Paul M. Ridker, Fernando Rivadeneira, Igor Rudan, A Ruokonen, Hubert Scharnagl, Janet Seeley, Kaisa Silander, Alena Stančáková, Kathleen Stirrups, Amy J. Swift, Laurence Tiret, André G. Uitterlinden, L. J. van Pelt(Translational Therapeutics (United States)), Sailaja Vedantam, Nicholas W.J. Wainwright, Cisca Wijmenga, Sarah H. Wild, Gonneke Willemsen, Tom Wilsgaard, James F. Wilson, Elizabeth Young, Wei Zhao, Linda S. Adair, Dominique Arveiler(Université de Strasbourg), Themistocles L. Assimes, Stefania Bandinelli, Franklyn I. Bennett, Murielle Bochud, Bernhard O. Boehm, Dorret I. Boomsma, Ingrid B. Borecki, Stefan R. Bornstein, Pascal Bovet, Michel Burnier, Harry Campbell, Aravinda Chakravarti, John C. Chambers, Yii‐Der Ida Chen, Francis S. Collins, Richard S. Cooper, George Dedoussis, Ulf dé Fairé, Alan B. Feranil, Luigi Ferrucci, Nelson B. Freimer, Christian Gieger, Leif Groop, Vilmundur Guðnason, Ulf Gyllensten, Anders Hamsten, Tamara B. Harris, Aroon D. Hingorani, Joel N. Hirschhorn, Albert Hofman, G. Kees Hovingh, Chao A. Hsiung, Steve E. Humphries, Steven C. Hunt, Kristian Hveem, Carlos Iribarren, Marjo‐Riitta Järvelin, Antti Jula, Mika Kähönen, Jaakko Kaprio, Antero Kesäniemi, Mika Kivimäki, Jaspal S. Kooner, Peter J. Koudstaal, Ronald M. Krauss, Diana Kuh, Johanna Kuusisto, Kirsten Ohm Kyvik, Markku Laakso, Timo A. Lakka, Lars Lind, Cecilia M. Lindgren, Nicholas G. Martin(Helmholtz Zentrum München), Winfried März, Mark I. McCarthy, Colin A. McKenzie, Pierre Meneton(Inserm), Andres Metspalu, Leena Moilanen, Andrew D. Morris, Patricia B. Munroe, Inger Njølstad, Nancy L. Pedersen, Chris Power(Western Infirmary), Peter P. Pramstaller, Jackie F. Price, Bruce M. Psaty, Thomas Quertermous, Rainer Rauramaa, Veikko Salomaa(Finnish Institute for Health and Welfare), Dharambir K. Sanghera, Jouko Saramies, Peter E. H. Schwarz, Wayne H.-H. Sheu, Alan R. Shuldiner, Agneta Siegbahn, Tim D. Spector, Kāri Stefánsson(Finnish Institute for Health and Welfare), David P. Strachan, Bamidele O. Tayo, Elena Tremoli, Jaakko Tuomilehto, Matti Uusitupa, Cornelia M. van Duijn, Péter Vollenweider, Lars Wallentin, Nicholas J. Wareham, John B. Whitfield, Bruce H. R. Wolffenbuttel, José M. Ordovás, Eric Boerwinkle, Colin N. A. Palmer, Unnur Þorsteinsdóttir, Daniel I. Chasman, Jerome I. Rotter, Paul W. Franks, Samuli Riatti, L. Adrienne Cupples, Manjinder S. Sandhu, Stephen S. Rich, Michael Boehnke, Panos Deloukas(Wellcome Sanger Institute), Karen L. Mohlke, Erik Ingelsson, Dongfeng Gu, Robert Roberts, Hugh Watkins, Stefan Blankenberg(Universität Hamburg), Robert Clarke, Rory Collins, Bong-Jo Kim, Ruth McPherson(University of Copenhagen), Markku S. Nieminen, Christopher J. O’Donnell, Stefan Schreiber(Universität Hamburg), Agneta Siegbahn, Pierre Zalloua
Science
March 10, 2016
Cited by 543Open Access
Full Text

Abstract

Scavenger receptor BI (SR-BI) is the major receptor for high-density lipoprotein (HDL) cholesterol (HDL-C). In humans, high amounts of HDL-C in plasma are associated with a lower risk of coronary heart disease (CHD). Mice that have depleted Scarb1 (SR-BI knockout mice) have markedly elevated HDL-C levels but, paradoxically, increased atherosclerosis. The impact of SR-BI on HDL metabolism and CHD risk in humans remains unclear. Through targeted sequencing of coding regions of lipid-modifying genes in 328 individuals with extremely high plasma HDL-C levels, we identified a homozygote for a loss-of-function variant, in which leucine replaces proline 376 (P376L), in SCARB1, the gene encoding SR-BI. The P376L variant impairs posttranslational processing of SR-BI and abrogates selective HDL cholesterol uptake in transfected cells, in hepatocyte-like cells derived from induced pluripotent stem cells from the homozygous subject, and in mice. Large population-based studies revealed that subjects who are heterozygous carriers of the P376L variant have significantly increased levels of plasma HDL-C. P376L carriers have a profound HDL-related phenotype and an increased risk of CHD (odds ratio = 1.79, which is statistically significant).


Related Papers